Genmab (GNMSF)
(Delayed Data from OTC)
$264.35 USD
+2.15 (0.82%)
Updated Sep 20, 2024 03:43 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
GNMSF 264.35 +2.15(0.82%)
Will GNMSF be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GNMSF based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for GNMSF
Undercovered Dozen: United Natural Foods, Procter & Gamble, Archer Aviation, Embraer +
Harding Loevner International Developed Markets Equity Q2 2024 Report
Harding Loevner International Equity ADR Q2 2024 Report
Harding Loevner International Equity Q2 2024 Report
Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab